Jubilant Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.jubilanttx.com
Jubilant Therapeutics Initiates Global Clinical Trials for JBI-802 and JBI-778 in Oncology
Jubilant Therapeutics has dosed the first patients in Phase I/II trials for JBI-802, targeting heme-oncology indications, showcasing their commitment to innovative cancer treatments.
Jubilant Therapeutics Initiates Clinical Trials for JBI-802 and JBI-778 in Oncology
Jubilant Therapeutics has dosed the first patients in global clinical trials for JBI-802, a first-in-class CoREST inhibitor, targeting heme-oncology malignancies.
© Copyright 2025. All Rights Reserved by MedPath